• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Clinical evaluation of Fufangkushen combined with oxaliplatin in the treatment of advanced colorectal cancer

    2022-12-12 11:52:30ZHOUTongWANGShuoHUShuaihangLIZhengFANBingjieLIJingleiHOUWei
    Journal of Hainan Medical College 2022年20期

    ZHOU Tong, WANG Shuo, HU Shuai-hang, LI Zheng, FAN Bing-jie, LI Jing-lei, HOU Wei?

    1. Guang' anmen Hospital Affiliated to China Academy of Chinese Medical Sciences, Beijing 100053, China

    2. China Academy of Chinese Medical Sciences, Beijing 100700, China

    Keywords:Fufangkushen Chemotherapy Advanced colorectal cancer Curative effect Security Meta analysis

    ABSTRACT Objective: To systematically evaluate the efficacy and safety of compound Kushen injection combined with oxaliplatin chemotherapy in the treatment of advanced colorectal cancer. Methods: We searched PubMed, EMbase, the Cochrane Library, CNKI, VIP and Wan Fang database, SinoMed to collect compound Kushen injection combined with chemotherapy oxaliplatin into treatment of advanced colorectal cancer in randomised controlled trials; the databases weresearched from inception to December 2020. Meta-analysis of the included studies was performed using RevMan 5.4. Results: A total of 34 randomized controlled trials involving 2 664 patients with colorectal cancer were included. Results of Meta-analysis showed that compound Kushen injection combined with oxaliplatin chemotherapy regimen improved the objective response rate of tumor [RR=1.40, 95%CI(1.29,1.51), P<0.000 01] and disease control rate [RR=1.12, 95%CI(1.08,1,16), P 0.000 01] improved the quality of life[RR=1.24, 95%CI(1.14,1.36), P<0.000 01], and significantly reduced the incidence of leukopenia[RR=0.35,95%CI(0.23,0.52), P<0.000 01] and the incidence of diarrhea [RR=0.36, 95%CI(0.19,0.70),P=0.003], and improved the immune function of patients (CD3+, CD4+, CD4+/CD8+, NK cell levels).However, compared to the control group, the levels of CD8+ cells were decreased in the experimental group. Conclusion: Compound Kushen injection combined with oxaliplatin chemotherapy regimen can significantly improve the clinical efficacy of advanced colorectal cancer patients, improve the quality of life of patients, reduce the occurrence of adverse reactions, and has good efficacy and safety comparison with oxaliplatin chemotherapy regimen alone.?Corresponding author: HOU Wei, Professer, Doctoral Supervisor.E-mail: houwei1964@163.com

    1. Introduction

    Colorectal cancer (CRC) is one of the most common malignant tumors in the world[1]. According to statistics, the incidence and mortality of CRC ranked the third among all malignant tumors in the world in 2020, and the incidence and mortality of CRC ranked the fifth among all malignant tumors in China[2-3]. Patients with early colorectal cancer can choose the treatment method of colonoscopy combined with surgery with a high cure rate, but about 30-50% of them will have recurrence and metastasis after radical resection [4], and most of them are diagnosed as advanced stage, in which case chemotherapy becomes the first treatment. Oxaliplatin chemotherapy regimen is currently the standard chemotherapy regimen for patients with advanced colorectal cancer [5], which

    often causes multiple adverse reactions, including bone marrow suppression, digestive tract reaction and peripheral neurotoxicity,which seriously affects the quality of life of patients. Many patients are forced to give up chemotherapy, and the clinical efficacy is greatly reduced [6].

    In recent years, compound Kushen Injection (CKI) with sophora and cocos as the main active components has been widely used in clinical practice, and has played a good role in inducing tumor cell apoptosis and promoting host anti-tumor immune response[7].Most of the previous studies comprehensively reviewed colorectal cancer patients at all pathological stages, and did not strictly limit the chemotherapy regimen, which could not provide guidance for the clinical treatment of advanced colorectal cancer patients with infeasible surgery or postoperative recurrence and metastasis. This article aims to fill this gap and conduct a rigorous meta-analysis of the Randomized controlled trial (RCT) of compound matrine injection combined with oxaliplatin in the treatment of advanced colorectal cancer, in order to evaluate its efficacy and safety and guide clinical application.

    2. Materials and methods

    2.1 Inclusion and exclusion criteria

    2.1.1 Study typesRandomized controlled trial (RCT) of compound Matrine injection combined with oxaliplatin in the treatment of advanced colorectal cancer.

    2.1.2 Types of ParticipantsAll enrolled patients met the 8th American Joint Committee on Cancer (AJCC) diagnostic criteria for advanced colorectal cancer [8]or Dukes stage. Stage Ⅲ-Ⅳ patients with pathology, cytology and imaging diagnosis of infeasible surgical treatment or postoperative recurrence and metastasis.

    2.1.3 Types of InterventionControl group: oxaliplatin chemotherapy regimen group (including FOLFOX regimen and XELOX regimen); Experimental group:On the basis of control group, compound Matrine injection was combined.

    2.1.4 Outcomes

    ① Clinical efficacy: Objective response rate (ORR) and disease control rate (DCR) were used to judge the clinical efficacy:According to the World Health Organization (WHO) efficacy evaluation criteria for solid tumors [9] and RECIST efficacy evaluation criteria for solid tumors [10], the patients were divided into complete response (CR), partial response (PR), stable response (SD)and progressive response (PD). Objective response rate = (CR +PR)/total number × 100%. Disease control rate = (CR cases +PR cases+SD cases)/total cases ×100%. ② Quality of life: Karnofsky(KPS score) improvement rate was used to evaluate the quality of life.After treatment, KPS score increased by 10 was considered as improved, decreased by 10 was considered as decreased,and changed by <10 was considered as stable. Improvement rate=(improved cases + stable cases)/total cases × 100%. ③ Safety:The incidence of adverse reactions was used as the outcome index of safety evaluation. According to the Criteria for Acute and subacute Toxicity of Chemotherapy Drugs formulated by WHO in 1981 [11],adverse reactions include bone marrow suppression (hemoglobin toxicity, leukocyte toxicity, platelet toxicity), digestive tract reactions(nausea and vomiting, diarrhea), peripheral neurotoxicity, and abnormal liver function. ④ Immune function: The proportion of immune cell subsets after treatment was used as the evaluation index of immune function. Including CD3+, CD4+, CD8+, CD4+/CD8+, NK.

    2.1.5 Exclusion criteria

    ① Non-chemotherapy means such as radiotherapy and targeted drugs were used. ② Use other traditional Chinese medicine preparations except compound Matrine injection. ③ Repeatedly published literature (the first paper was retained), or the research data of different literatures were duplicated (the paper with the most complete data retained). ④Complete research data could not be obtained.

    2.2 Research Strategy

    Chinese literature databases include China National Knowledge Infrastructure (CNKI), Chongqing VIP Chinese Science and Technology Journal Database (VIP), WanFang Database and China Biomedical Literature Service (SinoMed). The English databases are PubMed, EMBASE and Cochrane Library. Databases such as CLINICALTRIALS.GOV and WHO REGISTRY were manually searched for ongoing clinical trials or unpublished grey literature data. Retrieval date Self-built database to December 31, 2020.According to the RCT search strategy listed in Cochrane Systematic Review manual, the search terms were divided into two parts: target disease and intervention, and the combination of subject terms and free terms was used. The Chinese search terms were "colon cancer","rectal cancer", "colorectal cancer", "colorectal cancer", "compound matrine injection", "compound Matrine injection", "compound Matrine injection", "Yanshu injection", "Yanshu". The English search words are "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Compound Kushen Injection", "Fufangkushen","yanshu".

    2.3 Literature screening and data extraction

    By reading the title and abstract, the papers that obviously do not meet the inclusion criteria are excluded, and the full text is analyzed to determine whether to be included. The screening was performed by two investigators independently and cross-checked. In case of disagreement, the third investigator evaluated and handled the screening. In case of missing documents, contact the author by email or telephone to supplement them. The main contents of the extracted data include: ① basic information; ② Study population data; ③Intervention measures; ④ Control measures; ⑤ Outcome indicators.

    2.4 Literature quality evaluation

    The methodological quality of the included studies was assessed using the Cochrane Manual of Systematic Reviews 5.1.0 Risk of Bias Assessment tool. The evaluation included 7 aspects: random sequence generation, random concealment, patient/investigator blinding, outcome rater blinding, outcome data integrity, selective outcome reporting, and other sources of bias. Each evaluation Angle determines the risk type according to the risk of bias evaluation standard [12].

    2.5 Data synthesis

    Revman 5.4 software was used for statistical analysis. Clinical efficacy, quality of life and safety outcome indicators were dichotomous data, and relative risk (RR) was used as the effect indicator. The outcome index of immune function was continuous variable data, and the mean deviation (MD) was used as the effect index, and 95% confidence interval (CI) and P value were calculated. If P>0.1 and I250%, there was no significant statistical heterogeneity, and fixed effects model was used for analysis. If P 0.1 and I2>50%, the heterogeneity between studies was significant.Random effects model was used for analysis, and the source of heterogeneity was determined by sensitivity analysis or subgroup analysis. Funnel plots were used to analyze the publication bias of the included studies.

    3. Results

    3.1 Literature search results

    A total of 810 articles were retrieved from the database according to the retrieval strategy. The obtained articles were imported into NoteExpress software, and 503 duplicated articles were eliminated.By reading the title and abstract, 247 articles that did not meet the inclusion and exclusion criteria were excluded, and 26 articles with inconsistent baseline data or low literature quality were excluded from the full text of the remaining 60 articles. Finally, 34 RCTS were included. See Figure 1 for the literature screening process.

    3.2 Study Characteristics

    34 RCTs[13-46] were included, with a total sample size of 2 664 cases, including 1 343 cases in the experimental group and 1 321 cases in the control group. The minimum sample size was 21 cases and the maximum was 125 cases. The intervention measures in the control group included FOLFOX and XELOX chemotherapy regimens, while those in the experimental group were compound Matrine injection +FOLFOX/XELOX chemotherapy regimens.4 studies [30,31,38,40] course of treatment > 4 cycles, 23 studies courses 4 cycles. 16 [13,16,18,24,27,28,35,37,38-43,45,46] on the basis of KPS score grading evaluation of quality of life improved, 15 research [15,17,18,21,2428,34-38 9] are described, what is happening to adverse reactions In one study [13], the number of hemoglobin, white blood cells and platelets was detected by flow cytometry without grading. Specific literature characteristics are shown in Table 1.

    3.3 Quality evaluation of included studies

    Fig 1 Flowchart of literature screening

    Tab1 Document characteristic information table

    The 34 RCTS [13-46] included in the evaluation showed no statistically significant differences in baseline levels. Nine studies described stochastic methods, among which 7 studies [15,18-20,22,23,41] used random number table method,1 study [37] used stratified random equalization method, and 1 study [31] used computerized random blinding method. If the outcome indicators only included objective outcome indicators such as ORR and DCR, the implementation of blinding method would not affect the outcome bias, so it was evaluated as "low risk". If objective outcome indicators were not included, the risk of bias was evaluated as"high risk". If the outcome indicators included subjective outcome indicators such as quality of life and adverse reactions, the risk of bias was evaluated as "unclear". 34 RCTS [13-46] were not terminated early, and all of them had complete outcome reports. As shown in Figure 2.

    Fig 2 Assessment of risk of bias of the included studies

    3.4 Results of Meta-analysis

    3.4.1 Objective response rate

    3.4.1.1 WHO efficacy criteria for solid tumors 24 study [14,1622,24-28,30-32,34,36,38,40,41,43,44,46]using the WHO solid tumor curative effect evaluation standard for objective response rate statistics, statistical heterogeneity between studies smaller (P=0.42,I2= 3%), it USES the fixed effect model combined effect quantity.The results of meta-analysis showed that the experimental group could increase the ORR to 1.43 times of the control group, and the difference was statistically significant. (RR=1.43, 95%CI(1.31,1.55),P<0.000 01)

    3.4.1.2 RECIST Efficacy evaluation criteria for solid tumors

    The objective response rate of 7 studies [13,23,29,33,35,42,45] was calculated using the RECIST efficacy evaluation criteria for solid tumors. The statistical heterogeneity among the studies was small(P=0.96, I2=0%), so the effect size was pooled using the fixedeffect model. The results of meta-analysis showed that the ORR of the experimental group was better than that of the control group, and the difference was statistically significant. (RR=1.27,95%CI(1.051,1.54), P=0.01)

    Comprehensive data analysis showed that the objective remission rate of the experimental group was better than that of the control group, and the difference was statistically significant. (RR=1.40,95%CI(1.29,1.51), P<0.000 01). As shown in Figure 3.

    2.4.2 Disease control rate

    2.4.2.1 WHO efficacy criteria for solid tumors

    24 study[14,1622,24-28,30-32,34,36,38,40,41,43,44,46] using solid tumor WHO curative effect evaluation standard of disease control statistics,statistical heterogeneity between studies smaller (P = 0.39, I2=5%), it USES the fixed effect model combined effect quantity. The results of meta-analysis showed that DCR of the experimental group was better than that of the control group, and the difference was statistically significant. (RR=1.11, 95%CI(1.07,1.16), P < 0.000 01)

    3.4.2.2 Efficacy evaluation criteria of RECIST solid tumors

    The objective response rate of 7 studies[13,23,29,33,35,42,45] was calculated using the RECIST efficacy evaluation criteria for solid tumors. The statistical heterogeneity among the studies was small(P=0.79, I2=0%), so the effect size was pooled using the fixedeffect model. The results of meta-analysis showed that DCR of the experimental group was better than that of the control group, and the difference was statistically significant. (RR=1.13, 95%CI(1.03,1.24),P=0.01)

    Comprehensive data analysis showed that the disease control rate of the experimental group was better than that of the control group, and the difference was statistically significant.(RR=1.12,95%CI(1.08,1,16),P < 0.000 01).

    3.4.3 Quality of life evaluation

    16 [13,16,18,24,27,28,35,37,38-43,45,46] original data are stable and the number of cases in Karnofsky score growth or ratio of the total sum of the cases take statistics as the evaluation standard of quality of life improved, the statistical heterogeneity (P=0.006, I2=54%),so the random effect model was used to combine the effect sizes.The results of meta-analysis showed that the quality of life in the experimental group was better than that in the control group, and the difference was statistically significant. (RR=1.24, 95%CI(1.14,1.36),P < 0.000 01). As shown in Figure 5.

    Due to the moderate heterogeneity, the literature was excluded one by one for analysis. When the study of Gao Wei et al. [18] was excluded, the heterogeneity decreased to 23%, indicating that this study was the main source of heterogeneity. The oxaliplatin in the chemotherapy regimen of this study was 130 mg/m2, while the other studies were mostly 85 mg/m2or 100 mg/m2. Therefore, the source of heterogeneity was considered to be related to the high dose of chemotherapy drugs in this study.

    Fig 3 Forest plot of objective response rate

    3.4.4 Adverse reactions

    A total of 15 studies [15,17,18,21,2428,34-38,41] reported adverse reactions after treatment, and the detailed analysis results are shown in Table 2. Compared with the control group, experimental group to reduce the incidence of hemoglobin incidence, the incidence of leukopenia, thrombocytopenia, incidence of nausea and vomiting,diarrhea incidence, the incidence of peripheral nerve toxicity,reduced incidence of liver function damage, the results showed that compound sophora injection to reduce leukopenia and the incidence of adverse reactions of diarrhea curative effect is distinct,The difference was statistically significant(P<0.05). There was no significant difference in hemoglobin reduction rate between the experimental group and the control group(P>0.05).

    Due to heterogeneity in the rate of hemoglobin reduction, the incidence of nausea and vomiting, and the incidence of peripheral neurotoxicity, all indicators were removed from the study one by one for analysis. It was found that all the above indicators included this study, and the heterogeneity index of each indicator I2decreased to 0% after removal. And one by one to eliminate the remaining literature, statistical result of combined effect quantity and total amount effect were no significant difference, and statistical heterogeneity, there was no apparent change, illustrate Xi Rui’s research is the main source of heterogeneity, after the comprehensive analysis of research shows that the study intervention time about 6 cycles, as included in the study period is the elder, Therefore, the main reason for considering large heterogeneity is related to the long duration of treatment.

    Fig 4 Forest map of disease control rate

    3.4.5 Immune functionA total of 3 studies [15,20,24] have evaluated the immune function of patients, and the specific analysis results are shown in Table 3. Compared with the control group, the levels of CD3+, CD4+,CD4+/CD8+and NK cells in the experimental group were higher than those in the control group after treatment, and the differences were statistically significant(P<0.05). The level of CD8+cells in experimental group was lower than that in control group, and the difference was statistically significant(P<0.05). The heterogeneity of CD4+and CD8+ index was significant, which was considered to be related to the small number of studies and samples. Table 3.

    3.5 Publication bias

    Funnel plots were drawn for objective response rate and disease control rate, and it was found that the research distribution was relatively symmetrical and there was no obvious publication bias.See Figure 6 and 7.

    Tab 2 Meta-analysis of adverse reactions of CKI combined with oxaliplatin chemotherapy in the treatment of colorectal cancer

    Fig 5 Forest plot of quality of life

    Tab 3 Meta-analysis of immunologic function of CKI combined with oxaliplatin chemotherapy in the treatment of colorectal cancer

    Fig 6 Funnel plot of objective response rate

    Fig 7 Funnel plot of disease control rate

    4. Disscussion

    Past for CKI system evaluation is for the treatment of colorectal cancer are relationship, but more is the early, middle and late curative effect evaluation on the colorectal cancer study mixed together, did not give specific clinical staging of into the object of study, lead to clinical efficacy evaluation conclusion heterogeneity is bigger, can't give late infeasible the post-operation relapse and metastasis of CRC surgery or clinical practice provides guidance significance. In addition, previous studies have not restricted the chemotherapy intervention program, and the efficacy evaluation of FOLFOX, XELOX, FOLFIRL, chemotherapy combined with targeted therapy and immunotherapy is mixed, which is difficult to reflect the specific clinical efficacy of the first-line chemotherapy regimen of compound matrine injection combined with oxaliplatin alone. This study systematically evaluated the efficacy and safety of CKI combined with oxaliplatin in the treatment of advanced CRC from four aspects: clinical efficacy, quality of life, adverse reactions and immune function.

    In our country, the number of death cases caused by CRC is 187 100, accounting for 8.01% of all malignant tumor deaths [47]. The 5-year relative survival rate of stage Ⅰ colorectal cancer can reach 90%, while the 5-year relative survival rate of stage Ⅳ colorectal cancer with distant metastasis is only 14%[48]. At present, FOLFOX and XELOX chemotherapy regimens are the most commonly used first-line chemotherapy regimens in clinical practice [49]. Oxaliplatin is a third-generation platinum-based broad-spectrum cytotoxic drug,which belongs to DNA-damaging chemotherapy drugs containing 1,2-diaminocyclohexane group. Platinum atoms antagonize replication and transcription of DNA by cross-binding with DNA, and have obvious anti-cancer activity [5,50]. How to combine drugs to reduce the toxic and side effects of oxaliplatin chemotherapy regimen,improve the clinical efficiency of drug-resistant patients, and improve the quality of life of patients is an urgent clinical problem to be solved.

    CKI is the relationship of sophora and clay three flavour drug extracting effective ingredients of traditional Chinese medicine injection, has clear heat cool blood, fights the efficacy of detoxification, through the joint action of targets, mechanism, the comprehensive control proto-oncogenes and tumor suppressor gene,inducing tumor cell apoptosis, promote the host antitumor immune response, inhibit the formation of tumor angiogenesis [51] has good effect. Molecular biological studies have confirmed that CKI can affect the expression of BCL-2 proto-oncogene and telomerase,reduce the level of survivin, and induce apoptosis of tumor cells, so as to achieve anti-tumor effect [52]. Through in vitro experiments,Wang Hongqian et al. found that the CKI group, oxaliplatin group and the combination group had certain killing effects on colon cancer cell lines SW620, HT29 and LOVO, while the inhibition effect of the combination group on cell line proliferation was significantly stronger than that of the oxaliplatin group and CKI group, showing a dose-dependent effect [53].

    A total of 34 studies [13-46] were included in this study, including 2 664 patients, 1 343 in the experimental group and 1 321 in the control group. Results compared with oxaliplatin, CKI combined with oxaliplatin could improve the objective response rate of advanced CRC patients by about 17% and the disease control rate by about 9%, and the differences were statistically significant (P<0.05).At the same time, it can reduce the occurrence of adverse reactions such as bone marrow suppression, digestive tract reaction, liver function injury, peripheral neurotoxicity, especially in reducing the adverse reactions of leukopenia and diarrhea. In terms of immune function, CD3+reflects the level of cellular immunity of the body,while CD4+expands the immune response mainly by secreting lymphokines and plays a synergistic role with other immunizations.CD8+can inhibit CD4+cells and B cells [54]. The decrease of CD4+/CD8+ratio represents the decrease of cellular immune function in patients. As one of the evaluation criteria of anti-tumor, NK cells play an important role in immune surveillance and killing mutant cancer cells [55]. In the included study, the levels of CD3+, CD4+,CD4+/CD8+and NK in the experimental group were higher than those in the control group, while the levels of CD8+were lower than those in the control group, suggesting that CKI may improve the immune function of the body by enhancing CD3+, CD4+, CD4+/CD8+and NK.

    Limitations of this study: (1) The included study was a singlecenter study: all the included literatures were single-center studies,so the test efficacy was insufficient; (2) The methodological quality of the included studies was poor: most of the studies did not mention the evaluation report on the concealment of the randomized protocol and the degree of blinding implementation. In the study of tumor diseases, considering the side effects of chemotherapy and the long treatment cycle, it is difficult for patients to completely complete the treatment according to the predetermined protocol. However,34 studies [13-46] did not mention the situation of loss to follow-up or dropping off, so there is potential bias in the selective outcome report. (3) Lack of long-term outcome indicators in the included studies: Most of the outcome indicators of each study were based on clinical efficacy and quality of life. For example, there was only one study that analyzed the end points of clinical trials, such as progression-free survival, disease-free survival, and time to disease progression. There were too few data available for analysis,suggesting that other RCTS should pay attention to long-term survival indicators in the future. To provide research data for longterm clinical benefit of compound Matrine injection. (4) Different drug courses of included chemotherapy regimens: Although the drugs of specific chemotherapy regimens were strictly limited,there were differences in chemotherapy cycles among different studies, which would lead to potential bias in research conclusions.Therefore, large-sample, multicenter RCT is still needed for further verification.

    Author’s contribution:

    The first author, Zhou Tong, was responsible for the design and writing of the paper, and completed the literature screening and data extraction; Wang Shuo and Hu Shuai-hang were responsible for independently screening the literature and extracting data; Li Zheng and Fan Bing-jie checked and consulted and assisted in revising the format of the paper and related charts; Li Jing-lei was responsible for revising the paper; and corresponding author Hou Wei was responsible for topic selection, design and revision.

    All authors declare no conflict of interest.

    日本色播在线视频| 亚洲欧美中文字幕日韩二区| 日本-黄色视频高清免费观看| 伊人久久国产一区二区| av卡一久久| 女人精品久久久久毛片| 久久久久精品人妻al黑| 一二三四在线观看免费中文在 | 欧美国产精品一级二级三级| 精品福利永久在线观看| 久久精品熟女亚洲av麻豆精品| 一二三四在线观看免费中文在 | 欧美 亚洲 国产 日韩一| 日本wwww免费看| 99精国产麻豆久久婷婷| 日韩制服丝袜自拍偷拍| 国产精品久久久久久av不卡| 五月玫瑰六月丁香| 欧美精品一区二区免费开放| 亚洲国产精品999| 色婷婷久久久亚洲欧美| 国国产精品蜜臀av免费| 制服诱惑二区| 夫妻性生交免费视频一级片| 国产深夜福利视频在线观看| 王馨瑶露胸无遮挡在线观看| 成人国语在线视频| 久久久亚洲精品成人影院| 90打野战视频偷拍视频| 国产一区有黄有色的免费视频| 一本久久精品| 一级毛片电影观看| 日韩中字成人| 人成视频在线观看免费观看| 久久久久国产网址| 国产亚洲av片在线观看秒播厂| 国产成人a∨麻豆精品| 自拍欧美九色日韩亚洲蝌蚪91| 1024视频免费在线观看| 80岁老熟妇乱子伦牲交| 秋霞在线观看毛片| 啦啦啦视频在线资源免费观看| 久久久久精品久久久久真实原创| 免费观看在线日韩| 国产一区有黄有色的免费视频| 国产黄色视频一区二区在线观看| 久久ye,这里只有精品| av在线观看视频网站免费| 成人毛片60女人毛片免费| 国产福利在线免费观看视频| 久久狼人影院| 99热全是精品| 亚洲,一卡二卡三卡| 中文精品一卡2卡3卡4更新| 精品人妻偷拍中文字幕| 伦精品一区二区三区| 亚洲,欧美精品.| 亚洲精品乱久久久久久| 日本黄大片高清| 看免费成人av毛片| 日韩精品免费视频一区二区三区 | 久久久久久人人人人人| 久久精品国产综合久久久 | 丝袜在线中文字幕| 午夜91福利影院| 亚洲内射少妇av| 亚洲精品,欧美精品| 90打野战视频偷拍视频| 久久这里有精品视频免费| a级毛色黄片| 亚洲精品久久午夜乱码| 精品一区二区免费观看| 熟女电影av网| 国产精品久久久av美女十八| 久久精品夜色国产| av在线播放精品| 91久久精品国产一区二区三区| 欧美日韩精品成人综合77777| 一级毛片黄色毛片免费观看视频| 两个人免费观看高清视频| 97精品久久久久久久久久精品| 国产综合精华液| 日本vs欧美在线观看视频| 免费人妻精品一区二区三区视频| 中文字幕另类日韩欧美亚洲嫩草| 亚洲第一av免费看| 丝袜在线中文字幕| www日本在线高清视频| 人人妻人人添人人爽欧美一区卜| 亚洲熟女精品中文字幕| 中文字幕人妻丝袜制服| 午夜视频国产福利| 精品亚洲乱码少妇综合久久| 国产片特级美女逼逼视频| 国产片内射在线| 国产成人免费观看mmmm| 精品福利永久在线观看| 看免费成人av毛片| 在线观看人妻少妇| 亚洲av免费高清在线观看| 欧美少妇被猛烈插入视频| 亚洲av欧美aⅴ国产| 深夜精品福利| 少妇精品久久久久久久| 麻豆乱淫一区二区| 午夜免费鲁丝| 各种免费的搞黄视频| 精品国产一区二区久久| 肉色欧美久久久久久久蜜桃| 99re6热这里在线精品视频| 在线观看一区二区三区激情| 久久精品久久久久久久性| 18禁在线无遮挡免费观看视频| 男女边吃奶边做爰视频| 一区二区av电影网| 大话2 男鬼变身卡| 国产精品.久久久| 国产xxxxx性猛交| 亚洲图色成人| 黄色 视频免费看| 人妻人人澡人人爽人人| 校园人妻丝袜中文字幕| 免费不卡的大黄色大毛片视频在线观看| 国产极品天堂在线| 免费女性裸体啪啪无遮挡网站| 久久婷婷青草| 97在线人人人人妻| 亚洲精品国产av蜜桃| 亚洲成人一二三区av| 高清欧美精品videossex| 亚洲精品色激情综合| freevideosex欧美| 日韩一本色道免费dvd| 美女脱内裤让男人舔精品视频| 90打野战视频偷拍视频| 成人毛片60女人毛片免费| 女性生殖器流出的白浆| 日韩成人伦理影院| 亚洲欧美色中文字幕在线| 免费黄网站久久成人精品| 久久久久精品性色| 99九九在线精品视频| www.熟女人妻精品国产 | 丝瓜视频免费看黄片| 久久 成人 亚洲| 女人精品久久久久毛片| 亚洲色图 男人天堂 中文字幕 | 日本午夜av视频| 日韩一本色道免费dvd| 国产福利在线免费观看视频| 精品少妇黑人巨大在线播放| 欧美成人午夜免费资源| 久久人人爽人人片av| 夜夜骑夜夜射夜夜干| 国产亚洲欧美精品永久| 观看av在线不卡| av免费观看日本| 国产女主播在线喷水免费视频网站| 男的添女的下面高潮视频| 女性生殖器流出的白浆| 免费高清在线观看日韩| 九草在线视频观看| 十八禁网站网址无遮挡| 宅男免费午夜| 熟女av电影| 中国美白少妇内射xxxbb| 午夜视频国产福利| a级片在线免费高清观看视频| 男女无遮挡免费网站观看| 巨乳人妻的诱惑在线观看| 一个人免费看片子| 久久精品国产亚洲av天美| 又黄又爽又刺激的免费视频.| 日日啪夜夜爽| 免费少妇av软件| 国产午夜精品一二区理论片| 久久久a久久爽久久v久久| 国产欧美日韩一区二区三区在线| 九色亚洲精品在线播放| 亚洲精品国产av成人精品| 热re99久久国产66热| 成人18禁高潮啪啪吃奶动态图| 亚洲欧美成人综合另类久久久| 看非洲黑人一级黄片| 制服丝袜香蕉在线| 少妇精品久久久久久久| 边亲边吃奶的免费视频| 国产精品久久久久久av不卡| 色5月婷婷丁香| 性色av一级| 成年人午夜在线观看视频| 国产av国产精品国产| www.熟女人妻精品国产 | 韩国精品一区二区三区 | 婷婷色麻豆天堂久久| 最近最新中文字幕大全免费视频 | 在线天堂中文资源库| 色5月婷婷丁香| 精品视频人人做人人爽| 97在线人人人人妻| 久久久久久人人人人人| 黄网站色视频无遮挡免费观看| 欧美亚洲日本最大视频资源| 国产乱来视频区| 一边摸一边做爽爽视频免费| 麻豆精品久久久久久蜜桃| 热re99久久精品国产66热6| 啦啦啦啦在线视频资源| 香蕉精品网在线| 乱人伦中国视频| 韩国精品一区二区三区 | 丝袜人妻中文字幕| 久久99蜜桃精品久久| 国产精品无大码| 亚洲熟女精品中文字幕| 成人黄色视频免费在线看| 午夜av观看不卡| av在线观看视频网站免费| 91aial.com中文字幕在线观看| 成人毛片a级毛片在线播放| 天堂中文最新版在线下载| www.av在线官网国产| 伦理电影大哥的女人| 夫妻性生交免费视频一级片| 亚洲一区二区三区欧美精品| 大话2 男鬼变身卡| 制服丝袜香蕉在线| 午夜福利网站1000一区二区三区| 国产精品 国内视频| 亚洲欧美一区二区三区黑人 | 熟女av电影| 精品少妇黑人巨大在线播放| 黄色配什么色好看| 日韩精品免费视频一区二区三区 | 精品视频人人做人人爽| videos熟女内射| 欧美精品高潮呻吟av久久| 国产色爽女视频免费观看| 天天影视国产精品| 国产成人精品一,二区| 热re99久久精品国产66热6| 丝袜脚勾引网站| 99热6这里只有精品| 999精品在线视频| 韩国精品一区二区三区 | 国产精品一国产av| 亚洲色图 男人天堂 中文字幕 | 免费av中文字幕在线| 精品久久国产蜜桃| √禁漫天堂资源中文www| 欧美少妇被猛烈插入视频| 国产片内射在线| 狂野欧美激情性xxxx在线观看| 久久久久久久精品精品| 欧美日韩国产mv在线观看视频| 水蜜桃什么品种好| 精品99又大又爽又粗少妇毛片| 国产精品久久久av美女十八| 久久av网站| 欧美日本中文国产一区发布| 国产女主播在线喷水免费视频网站| 黄片无遮挡物在线观看| 成人国产麻豆网| 少妇的逼好多水| 国产精品久久久久久av不卡| 国产乱来视频区| 久久久久久久国产电影| 久久狼人影院| 国产高清不卡午夜福利| 国产黄频视频在线观看| 国产一区亚洲一区在线观看| 免费观看性生交大片5| 日韩 亚洲 欧美在线| 亚洲伊人色综图| 18+在线观看网站| av.在线天堂| 哪个播放器可以免费观看大片| 欧美精品国产亚洲| 看免费av毛片| 热99国产精品久久久久久7| 纯流量卡能插随身wifi吗| 精品一区二区三卡| 人体艺术视频欧美日本| 欧美亚洲 丝袜 人妻 在线| 少妇人妻久久综合中文| 天堂8中文在线网| 免费大片18禁| 亚洲综合精品二区| 亚洲精品中文字幕在线视频| 成人综合一区亚洲| 波野结衣二区三区在线| 欧美亚洲 丝袜 人妻 在线| freevideosex欧美| 日日撸夜夜添| 在线观看免费高清a一片| 免费黄色在线免费观看| 夜夜爽夜夜爽视频| 国产白丝娇喘喷水9色精品| 欧美xxⅹ黑人| 精品国产乱码久久久久久小说| 久久午夜综合久久蜜桃| 我要看黄色一级片免费的| 啦啦啦啦在线视频资源| 亚洲人成网站在线观看播放| 美女脱内裤让男人舔精品视频| 国产熟女午夜一区二区三区| 一级a做视频免费观看| 视频中文字幕在线观看| 久久精品夜色国产| 国产免费又黄又爽又色| 国产一区二区三区综合在线观看 | 亚洲,一卡二卡三卡| 97人妻天天添夜夜摸| 新久久久久国产一级毛片| 国产欧美亚洲国产| 亚洲精品视频女| 欧美精品国产亚洲| 咕卡用的链子| 中文字幕亚洲精品专区| av视频免费观看在线观看| 中文字幕另类日韩欧美亚洲嫩草| 国产极品粉嫩免费观看在线| 黄片播放在线免费| 国产成人aa在线观看| av在线老鸭窝| 久久久久久久久久久免费av| 中文欧美无线码| 在线观看国产h片| 久久久久网色| 久久久国产欧美日韩av| 免费av不卡在线播放| 99热国产这里只有精品6| 嫩草影院入口| 少妇精品久久久久久久| 色网站视频免费| 欧美人与性动交α欧美精品济南到 | 丰满迷人的少妇在线观看| 一本大道久久a久久精品| 国产精品蜜桃在线观看| 亚洲第一av免费看| 欧美xxⅹ黑人| 久久久久精品久久久久真实原创| 欧美激情 高清一区二区三区| 日韩熟女老妇一区二区性免费视频| 亚洲经典国产精华液单| 一区在线观看完整版| 一级a做视频免费观看| 春色校园在线视频观看| 日韩制服丝袜自拍偷拍| videosex国产| 哪个播放器可以免费观看大片| 天堂8中文在线网| 久久久久国产精品人妻一区二区| 欧美精品高潮呻吟av久久| 日本免费在线观看一区| 日韩制服骚丝袜av| 男男h啪啪无遮挡| 美女视频免费永久观看网站| 另类亚洲欧美激情| 精品福利永久在线观看| av又黄又爽大尺度在线免费看| 老司机亚洲免费影院| 亚洲国产毛片av蜜桃av| 全区人妻精品视频| 美女国产视频在线观看| 国内精品宾馆在线| 久久精品国产a三级三级三级| 91精品三级在线观看| 国产黄频视频在线观看| 18禁在线无遮挡免费观看视频| 丁香六月天网| 欧美日韩综合久久久久久| 精品一区二区三区四区五区乱码 | 久久久久久久久久久免费av| 香蕉国产在线看| 青春草亚洲视频在线观看| 亚洲av综合色区一区| 一级爰片在线观看| 九九在线视频观看精品| 桃花免费在线播放| 精品久久久精品久久久| av在线老鸭窝| 亚洲人成77777在线视频| 亚洲av成人精品一二三区| 久久午夜福利片| videos熟女内射| 精品国产一区二区三区久久久樱花| 色婷婷av一区二区三区视频| 少妇猛男粗大的猛烈进出视频| 国产欧美日韩一区二区三区在线| 亚洲中文av在线| 欧美bdsm另类| 最后的刺客免费高清国语| 99久久人妻综合| 熟女电影av网| 久久这里只有精品19| 99久久综合免费| 一级爰片在线观看| 男女下面插进去视频免费观看 | 亚洲精品国产av蜜桃| 宅男免费午夜| 最新的欧美精品一区二区| 97在线视频观看| 免费黄色在线免费观看| 国产一区二区激情短视频 | 三上悠亚av全集在线观看| 99re6热这里在线精品视频| 免费在线观看黄色视频的| 亚洲国产最新在线播放| 国产免费又黄又爽又色| 精品人妻偷拍中文字幕| 国产成人av激情在线播放| 中文字幕免费在线视频6| 精品国产露脸久久av麻豆| 多毛熟女@视频| 欧美亚洲日本最大视频资源| 女性生殖器流出的白浆| 最近最新中文字幕免费大全7| 亚洲四区av| 免费在线观看完整版高清| 国产精品一国产av| 18禁在线无遮挡免费观看视频| 新久久久久国产一级毛片| 母亲3免费完整高清在线观看 | 亚洲精品aⅴ在线观看| 9色porny在线观看| 国产深夜福利视频在线观看| 日本-黄色视频高清免费观看| 国产成人精品婷婷| 在线观看www视频免费| 欧美日本中文国产一区发布| 桃花免费在线播放| 亚洲五月色婷婷综合| 亚洲精品美女久久久久99蜜臀 | 精品一区二区三区四区五区乱码 | 插逼视频在线观看| 寂寞人妻少妇视频99o| 亚洲精品视频女| av网站免费在线观看视频| 人成视频在线观看免费观看| 免费观看av网站的网址| 久久久久精品久久久久真实原创| 免费观看无遮挡的男女| 丝瓜视频免费看黄片| 最近最新中文字幕大全免费视频 | 伦理电影免费视频| 亚洲伊人色综图| 日本黄大片高清| 大码成人一级视频| 久久精品夜色国产| 欧美激情国产日韩精品一区| 一本—道久久a久久精品蜜桃钙片| 男人爽女人下面视频在线观看| 蜜桃在线观看..| 最黄视频免费看| 在线 av 中文字幕| 多毛熟女@视频| 18禁在线无遮挡免费观看视频| 夜夜爽夜夜爽视频| 成人手机av| 精品少妇内射三级| 欧美精品高潮呻吟av久久| 欧美精品一区二区免费开放| 国产成人a∨麻豆精品| 日本欧美视频一区| 国产黄频视频在线观看| 亚洲欧美中文字幕日韩二区| 99re6热这里在线精品视频| 日韩三级伦理在线观看| 999精品在线视频| 你懂的网址亚洲精品在线观看| 久久影院123| 极品少妇高潮喷水抽搐| 亚洲精品,欧美精品| av卡一久久| 国产成人午夜福利电影在线观看| 久久这里只有精品19| 97精品久久久久久久久久精品| 老司机影院毛片| 久久久久人妻精品一区果冻| av在线app专区| 成人手机av| 欧美国产精品va在线观看不卡| 亚洲国产日韩一区二区| 在线观看三级黄色| 久久久久久久大尺度免费视频| 日韩一本色道免费dvd| 美女内射精品一级片tv| 午夜视频国产福利| 各种免费的搞黄视频| 丝袜在线中文字幕| 欧美日韩一区二区视频在线观看视频在线| 久久影院123| 男女无遮挡免费网站观看| 久久精品久久久久久噜噜老黄| 51国产日韩欧美| 国产熟女欧美一区二区| 在线观看美女被高潮喷水网站| 久久久久久久亚洲中文字幕| 中文字幕人妻熟女乱码| 午夜激情av网站| 最近中文字幕2019免费版| 久久综合国产亚洲精品| 久久久国产欧美日韩av| 国产精品一国产av| 亚洲国产精品成人久久小说| 日韩熟女老妇一区二区性免费视频| 97在线视频观看| 久久久国产欧美日韩av| 欧美日韩精品成人综合77777| 最近的中文字幕免费完整| 久久国产精品大桥未久av| 亚洲欧洲精品一区二区精品久久久 | 国内精品宾馆在线| 久久av网站| 日韩三级伦理在线观看| 在线亚洲精品国产二区图片欧美| 永久免费av网站大全| 在线观看免费高清a一片| a级片在线免费高清观看视频| 亚洲国产欧美在线一区| 九九爱精品视频在线观看| 欧美精品一区二区免费开放| 水蜜桃什么品种好| 午夜福利在线观看免费完整高清在| 一区二区三区四区激情视频| 18+在线观看网站| 久久人人爽人人爽人人片va| 18禁动态无遮挡网站| 国产黄频视频在线观看| 成年人午夜在线观看视频| 久久精品人人爽人人爽视色| 色视频在线一区二区三区| 亚洲精品久久成人aⅴ小说| 亚洲国产精品专区欧美| 18禁观看日本| 国产极品天堂在线| 欧美国产精品va在线观看不卡| 免费大片黄手机在线观看| 精品第一国产精品| 久久精品熟女亚洲av麻豆精品| 国产麻豆69| 飞空精品影院首页| 欧美亚洲 丝袜 人妻 在线| 国产片特级美女逼逼视频| 国产精品一区二区在线观看99| av在线播放精品| 国产伦理片在线播放av一区| 精品久久国产蜜桃| 国产高清三级在线| 成人国产麻豆网| 美女视频免费永久观看网站| 汤姆久久久久久久影院中文字幕| 日韩 亚洲 欧美在线| 成人毛片60女人毛片免费| 春色校园在线视频观看| 久久女婷五月综合色啪小说| 又大又黄又爽视频免费| 飞空精品影院首页| 91aial.com中文字幕在线观看| 三级国产精品片| 日韩av不卡免费在线播放| 在线 av 中文字幕| 日本黄大片高清| 毛片一级片免费看久久久久| 国产不卡av网站在线观看| 伦理电影免费视频| 成人午夜精彩视频在线观看| 精品久久蜜臀av无| 国产日韩欧美在线精品| 日日撸夜夜添| 99久久人妻综合| av片东京热男人的天堂| 久久精品国产a三级三级三级| 国产精品秋霞免费鲁丝片| 三上悠亚av全集在线观看| 男人操女人黄网站| 秋霞在线观看毛片| 亚洲精品久久久久久婷婷小说| 久久久久国产精品人妻一区二区| 22中文网久久字幕| 97人妻天天添夜夜摸| 大话2 男鬼变身卡| 中文字幕精品免费在线观看视频 | 欧美精品av麻豆av| 国产精品不卡视频一区二区| 成人影院久久| 宅男免费午夜| 在线观看美女被高潮喷水网站| 熟女av电影| 久久人人爽人人爽人人片va| 美女中出高潮动态图| 欧美国产精品一级二级三级| 赤兔流量卡办理| 一级毛片电影观看| av视频免费观看在线观看| 精品一区在线观看国产| 国产精品人妻久久久久久| 国产精品一区二区在线不卡| 亚洲精华国产精华液的使用体验| 国产日韩一区二区三区精品不卡| 亚洲欧美成人精品一区二区| 国产高清国产精品国产三级| 欧美老熟妇乱子伦牲交| 国产片内射在线| 深夜精品福利| 最近中文字幕高清免费大全6| 国产一区二区三区综合在线观看 | 人妻 亚洲 视频| 9色porny在线观看| 不卡视频在线观看欧美| 91精品伊人久久大香线蕉| 国产免费视频播放在线视频| 欧美日韩一区二区视频在线观看视频在线| 午夜福利影视在线免费观看|